Supriya Lifescience (NSE:SUPRIYA) Other Current Receivables: ₹6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SUPRIYA Supriya Lifescience Ltd NSE:SUPRIYA
81 GF Score
Price ₹923.45
GF Value ₹811.82
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Supriya Lifescience Other Current Receivables?

Supriya Lifescience NSE:SUPRIYA +3.66% 81 Other Current Receivables is ₹6 Mil as of Mar. 2026. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 81/100 and a GF Value™ of ₹811.82 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Supriya Lifescience's Other Current Receivables for the quarter that ended in Mar. 2026 was ₹6 Mil.

Supriya Lifescience's quarterly Other Current Receivables declined from Sep. 2025 (₹8.20 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹5.69 Mil).

Supriya Lifescience's annual Other Current Receivables declined from Mar. 2024 (₹54.06 Mil) to Mar. 2025 (₹16.38 Mil) and declined from Mar. 2025 (₹16.38 Mil) to Mar. 2026 (₹5.69 Mil).

Supriya Lifescience Other Current Receivables Related Terms

Supriya Lifescience Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Supriya Lifescience's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supriya Lifescience Other Current Receivables Chart

Supriya Lifescience Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial 239.76 69.55 54.06 16.38 5.69

Supriya Lifescience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.38 0.00 8.20 0.00 5.69
NSE:SUPRIYA
81GF Score
Supriya Lifescience Ltd NSE:SUPRIYA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supriya Lifescience Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹6 Mil mean?
Supriya Lifescience (NSE:SUPRIYA) has a Other Current Receivables of ₹6 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Supriya Lifescience and its competitors.
Is Supriya Lifescience's Other Current Receivables too high?
Supriya Lifescience's current Other Current Receivables is ₹6 Mil. Overall, Supriya Lifescience has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Other Current Receivables compare to VRTX and REGN?
Supriya Lifescience's Other Current Receivables of ₹6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Supriya Lifescience and its competitors. Supriya Lifescience's current Other Current Receivables is ₹6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹811.82, compared to a current price of ₹923.45 — trading 13.8% above its estimated fair value. The current Other Current Receivables is ₹6 Mil. Supriya Lifescience's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Other Current Receivables is ₹6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?

Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued. The current stock price of ₹923.45 is trading 13.8% above its estimated GF Value™ of ₹811.82. GuruFocus considers Supriya Lifescience to be Modestly Overvalued.

Key valuation signals for NSE:SUPRIYA:

  • Other Current Receivables: ₹6 Mil
  • GF Value™: ₹811.82 vs. price of ₹923.45 (13.8% above fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supriya Lifescience Business Description

Other Exchanges 543434:India
Address Sonawala Road, 207/208, Udyog Bhavan, Goregaon East, Mumbai, MH, IND, 400063
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
81GF Score

Get the complete analysis for NSE:SUPRIYA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹923.45
Price
₹811.82
GF Value